TRANSDUR transdermal patch technology is focused on achieving either of two goals, depending on the clinical need:

  • Topical treatment of disorders localized to discrete areas of skin
  • Efficient parenteral delivery of drugs with low oral bioavailabilities or short durations of action

Investigational products in the TRANSDUR family are highly customizable according to the active agent and therapeutic goal. Large-area patches are designed to provide topical treatment to broad areas of affected skin, whereas smaller patches are intended to deliver drugs to the systemic circulation over extended periods.

TRANSDUR transdermal systems are designed with the following objectives in mind:

  • Excellent skin adhesion
  • Minimal irritation potential, even after long-term contact
  • Solid-state drug reservoir for safety and efficient drug transfer
  • 3- to 7-day continuous drug delivery with specialized rate-controlling chemistries

TRANSDUR technology underlies two investigational products: the large-area ELADUR® (TRANSDUR-Bupivacaine) patch, proposed for the treatment of postherpetic neuralgia, and the small-area TRANSDUR®-Sufentanil patch, envisioned for the treatment of chronic pain.

TRANSDUR-based products are investigational and have not been approved by the FDA for marketing in the U.S. for any indication. Opioids such as sufentanil expose patients to risks of addiction, abuse, and misuse.

Learn more about TRANSDUR-based pipeline products:

ELADUR® (TRANSDUR®-Bupivacaine)